Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 12, 2010, Pages 1704-1710

  Coburger, Claudius ^a   Lage, Hermann ^b   Molnár, Joséf ^c   Langner, Andreas ^a   Hilgeroth, Andreas ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cytotoxicity; HIV 1 protease inhibitor; Multidrug resistance modulators; P glycoprotein

Indexed keywords

GLYCOPROTEIN P; H 17; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HW 41; JW 33; JW 41; JW 46; RITONAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; EVALUATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; STOMACH CARCINOMA;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; HEP G2 CELLS; HIV PROTEASE INHIBITORS; HUMANS; JURKAT CELLS; LYMPHOMA, T-CELL; MICE; MITOCHONDRIA; P-GLYCOPROTEIN; RITONAVIR;

EID: 78149363515     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01144.x     Document Type: Article

References (29)

1. Goldman B. Can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 2003; 95: 255-257.
2. Kim RB et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
3. Larson AK et al. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000; 85: 217-229.
4. Mahon F et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
5. Matsui H et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16: 813-819.
6. Gottesmann MM, Pastan, I. Multidrug resistance in cancer: the role of ATP dependent transporters. Nat Rev Cancer 2002; 2: 28-58.
7. Huang Y, Sadée W. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett 2006; 239: 168-182.
8. Murakami S et al. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 2002; 419: 587-593.
9. Sheps JA, Ling V. Preface: the concept and the consequences of multidrug resistance. Eur J Physiol 2007; 453: 545-553.
10. Avendanó C, Menéndez JC. Recent advances in multidrug resistance modulators. Med Chem Rev-Online 2004; 1: 419-444.
11. Baumert C, Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem 2009; 9: 415-436.
12. Wang RB et al. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003; 28: 203-228.
13. Chang C et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984.
14. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
15. Sharom FJ. ABC multidrug transporters: structure, function and the role in chemoresistance. Pharmacogenomics 2008; 9: 105-127.
16. Huisman MT et al. P-Glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59: 806-813.
17. Wollmann J et al. Novel insight into the inhibitor binding of highly symmetric HIV-1 protease. ChemBioChem 2008; 9: 874-878.
18. Lage H et al. Thermosensitivity of multidrug-resistant human gastric and pancreatic carcinoma cells. Int J Hyperthermia 2000; 16: 291-303.
19. Voigt B. et al. Structure-activity relationships of novel N-acyloxy-1, 4-dihydropyridines as P-glycoprotein inhibitors. Bioorg Med Chem 2007; 15: 5110-5113.
20. Lee J et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer institute drug screen. Mol Pharm 1994; 46: 627-628.
21. Coburger C. et al. Novel insight in structure-activity relationship and bioanalysis of p-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3, 9-diazatetraasteranes. J Med Chem 2008; 51: 5871-5874.
22. Drewe J et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999; 57: 1147-1152.
23. Mühlenfeld K, Langner A. Biotransformation and toxicity of the lipoxygenase inhibitor 2-hydroxy-5-methyllaurophenone oxime (FLM 5011) on HepG2 cells. Arch Pharm Pharm Med Chem 1998; 331: 259-261.
24. Reed JC. Apoptosis mechanisms: implications for cancer drug discovery. Oncology 2004; 18: 11-20.
25. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
26. Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 2003; 4: 137-143.
27. Deray G et al. Nephrotoxicity of ritonavir. Presse Med 1998; 35: 1801-1803.
28. Lee G, Piquette-Miller M. Influence of Il-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 2001; 79: 876-884.
29. Tong AW et al. Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma. Clin Res Cancer 1996; 2: 531-539.